Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2013-10-22
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 36
- Registration Number
- NCT00633529
- Locations
- 🇺🇸
Mary Crowley Medical Research Center, Dallas, Texas, United States
🇺🇸Central Indiana Cancer Centers, Indianapolis, Indiana, United States
🇺🇸Cancer Therapy and Research Center, San Antonio, Texas, United States
Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)
- Conditions
- Interventions
- First Posted Date
- 2008-02-27
- Last Posted Date
- 2016-03-14
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 461
- Registration Number
- NCT00624338
- Locations
- 🇺🇸
Justus J. Fiechtner, MD, MPH, Lansing, Michigan, United States
🇺🇸Inland Rheumatology Clinical Trials Inc, Upland, California, United States
🇬🇧Research Site, Manchester, United Kingdom
Atacicept in Subjects With Optic Neuritis
- Conditions
- Interventions
- First Posted Date
- 2008-02-27
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 34
- Registration Number
- NCT00624468
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom
Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)
- Conditions
- Interventions
- First Posted Date
- 2008-01-16
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 311
- Registration Number
- NCT00595413
- Locations
- 🇩🇪
Please contact the Merck KGaA Communication Center, Darmstadt, Germany
🇺🇸Please Contact US Medical Information, Rockland, Massachusetts, United States
The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis
- Conditions
- Interventions
- First Posted Date
- 2007-12-14
- Last Posted Date
- 2016-03-23
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 6
- Registration Number
- NCT00573157
- Locations
- 🇺🇸
1711 St. Julian Place, Columbia, South Carolina, United States
🇺🇸The Feinstein Institute for Medical Research, Manhasset, New York, United States
🇲🇾Hospital Sultanah Bahiyah, Kedah, Malaysia
Growth Hormone in the Treatment of HIV-Associated Wasting
- Conditions
- First Posted Date
- 2007-06-21
- Last Posted Date
- 2013-10-22
- Lead Sponsor
- EMD Serono
- Registration Number
- NCT00489528
Rebif New Formulation (RNF) Quality of Life (QOL) Study
- Conditions
- Interventions
- First Posted Date
- 2007-05-14
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 232
- Registration Number
- NCT00472797
- Locations
- 🇺🇸
EMD Serono, Inc., Rockland, Massachusetts, United States
A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I)
- Conditions
- Interventions
- First Posted Date
- 2007-02-02
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 256
- Registration Number
- NCT00430495
- Locations
- 🇨🇦
Merck/Serono, Canada, Canada
🇺🇸EMD Serono, Rockland, Massachusetts, United States
RNF and Betaseron® Tolerability Study
- Conditions
- Interventions
- First Posted Date
- 2007-01-30
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 129
- Registration Number
- NCT00428584
- Locations
- 🇺🇸
EMD Serono Med Info, Rockland, Massachusetts, United States
Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)
- Conditions
- Interventions
- First Posted Date
- 2006-12-08
- Last Posted Date
- 2015-11-20
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 1513
- Registration Number
- NCT00409188
- Locations
- 🇺🇸
Deaconess Billings Clinic, Billings, Montana, United States
🇺🇸University of Maryland, Marlene and Steward Greenbaum Cancer Center, Baltimore, Maryland, United States
🇺🇸Cedars-Sinai Outpatient Cancer Center at the Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States